Bmc Pediatr
-
Clinical Trial Controlled Clinical Trial
Safety of a new extensively hydrolysed formula in children with cow's milk protein allergy: a double blind crossover study.
Formulae for infants with cow's milk protein allergy (CMA) should be based on extensively hydrolysed protein. 'Extensively' however is not strictly defined. Differences in molecular weight and peptide chain length may affect its clinical outcome. We studied the safety of a new extensively hydrolysed casein based formula (Frisolac Allergycare: FAC) for children with IgE mediated CMA. ⋯ The new extensively hydrolysed casein-based formula (FAC) can safely be used in children with IgE mediated cow's milk allergy.